MedPage Today on MSN4d
GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without DiabetesThe number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual ...
Ozempic and Trulicity belong to the same group of drugs, called glucagon-like peptide-1 (GLP-1) receptor agonists. Mounjaro belongs to a similar group of drugs, called GLP-1 and glucose-dependent ...
New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...
GLP-1 agonists may lead to increased nausea and vomiting in the early postoperative period after total hip arthroplasty, ...
Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...
The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...
The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...
Researchers say payers should take the added costs of drugs prescribed to deal with GLP-1 side effects into account when ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback